Roivant Sciences Ltd. Common Shares (ROIV) Financial Statements
Historical financial data — 18 statements covering FY2022–FY2024
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology...
Roivant Sciences Ltd. Common Shares's revenue decreased 52.6% year over year, from $61.3M to $29.1M.
Net income increased 83.0% over the same period, from $-1.01B to $-172.0M.
Operating cash flow grew 0.5% to $-839.5M.
Roivant Sciences Ltd. Common Shares maintains a negative net profit margin of -592.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $37.1M+0.1% | $5.10B | N/A | $5.06B | $-210.5M | $7.31B | $403.3M | $6.09B |
| Q1 FY2024 | $55.1M+48.4% | $95.3M | N/A | $-120.2M | $-192.8M | $6.50B | $311.7M | $5.44B |
| Q2 FY2024 | $-42.7M-177.4% | $-230.2M | N/A | $-323.8M | $-266.8M | $6.21B | N/A | $5.15B |
| Q3 FY2024 | $9.0M+121.1% | $169.4M | N/A | $-274.4M | $-207.3M | $5.79B | N/A | $5.19B |
| Q4 FY2024 | $7.6M-16.1% | $-206.5M | N/A | $-285.0M | $-172.6M | $5.44B | N/A | $4.69B |
| Q1 FY2025 | $2.2M-71.3% | $-223.4M | N/A | $-284.9M | $-204.4M | $5.03B | N/A | $4.35B |
| Q2 FY2025 | $1.6M-27.6% | $-113.5M | N/A | $-306.2M | $-185.7M | $5.06B | N/A | $4.36B |
| Q3 FY2025 | $2.0M+27.2% | $-265.9M | N/A | $-339.2M | $-196.5M | $5.23B | N/A | $4.27B |
Balance Sheet Summary (Latest Period)
Roivant Sciences Ltd. Common Shares (ROIV) Financial Statements & Revenue History
Roivant Sciences Ltd. Common Shares (ROIV) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $35.80 with a market capitalization of $26. This page provides 18 historical financial statements for Roivant Sciences Ltd. Common Shares, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Roivant Sciences Ltd. Common Shares reported revenue of $29 million, a 52.6% decline from the prior year. The net profit margin of -592.0% indicates the company is currently unprofitable..
ROIV Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Roivant Sciences Ltd. Common Shares's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ROIV is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ROIV's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Roivant Sciences Ltd. Common Shares converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ROIV's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ROIV Financial Data
Investors use Roivant Sciences Ltd. Common Shares's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ROIV's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ROIV's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ROIV's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Roivant Sciences Ltd. Common Shares's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ROIV trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.